The potential impact of recombinant factor VIII on hemophilia care and the demand for blood and blood products.
VanAken
W G
WG
Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
D000163:Acquired Immunodeficiency Syndrome / Q000635:transmission; D001798:Blood Proteins / Q000737:chemistry / Q000627:therapeutic use; D005169:Factor VIII / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000821:virology; D006506:Hepatitis A / Q000635:transmission; D006526:Hepatitis C / Q000635:transmission; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
D001798:Blood Proteins; D011994:Recombinant Proteins; D005169:Factor VIII